Latest Insider Transactions at Lumos Pharma, Inc. (LUMO)
This section provides a real-time view of insider transactions for Lumos Pharma, Inc. (LUMO). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of LUMOS PHARMA, INC. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of LUMOS PHARMA, INC.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
May 20
2021
|
An Van Es Johansson Director |
BUY
Grant, award, or other acquisition
|
Direct |
367
+25.02%
|
-
|
|
May 20
2021
|
Lota S. Zoth Director |
BUY
Grant, award, or other acquisition
|
Direct |
367
+14.37%
|
-
|
|
Apr 01
2021
|
Richard J Hawkins Chief Executive Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,522
-0.2%
|
$18,264
$12.25 P/Share
|
|
Apr 01
2021
|
Carl W. Langren Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
683
-5.61%
|
$8,196
$12.25 P/Share
|
|
Apr 01
2021
|
Lori D Lawley Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
274
-4.8%
|
$3,288
$12.25 P/Share
|
|
Apr 01
2021
|
John C. Mc Kew Chief Scientific Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,036
-7.26%
|
$12,432
$12.25 P/Share
|
|
Apr 01
2021
|
Bradley J Powers General Counsel |
SELL
Payment of exercise price or tax liability
|
Direct |
342
-6.31%
|
$4,104
$12.25 P/Share
|
|
Feb 01
2021
|
Richard J Hawkins Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
2,329
+0.31%
|
-
|
|
Feb 01
2021
|
Eugene P. Kennedy Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
939
+7.6%
|
-
|
|
Feb 01
2021
|
Carl W. Langren Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
939
+7.16%
|
-
|
|
Feb 01
2021
|
Lori D Lawley Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
869
+13.21%
|
-
|
|
Feb 01
2021
|
John C. Mc Kew Chief Scientific Officer |
BUY
Grant, award, or other acquisition
|
Direct |
1,078
+7.03%
|
-
|
|
Feb 01
2021
|
Bradley J Powers General Counsel |
BUY
Grant, award, or other acquisition
|
Direct |
869
+13.81%
|
-
|
|
Jan 08
2021
|
James E Flynn > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
106,512
-4.01%
|
$2,449,776
$23.31 P/Share
|
|
Jan 07
2021
|
James E Flynn > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
16,172
-0.89%
|
$388,128
$24.7 P/Share
|
|
Jan 06
2021
|
James E Flynn > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
29,039
-1.55%
|
$638,858
$22.55 P/Share
|